Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis

Ernst-Wilhelm Radue, MD; Paul O'Connor, MD; Chris H. Polman, MD; Reinhard Hohlfeld, MD; Peter Calabresi, MD; Krystof Selmaj, MD; Nicole Mueller-Lenke, MD; Catherine Agoropoulou, PhD; Frederick Holdbrook, PhD; Ana de Vera, MD; Lixin Zhang-Auberson, MD; Gordon Francis, MD; Pascale Burtin, MD; Ludwig Kappos, MD; for the FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group

Objective: To assess the impact of fingolimod (FTY720) therapy on magnetic resonance imaging measures of inflammatory activity and tissue damage in patients participating in a 2-year, placebo-controlled, phase 3 study.

Design: Patients with active relapsing-remitting multiple sclerosis were randomized to receive fingolimod, 0.5 mg; fingolimod, 1.25 mg; or placebo for 2 years. Standardized magnetic resonance imaging scans were obtained at months 0, 6, 12, and 24 and centrally evaluated for number and volume of T1 gadolinium-enhancing, T2 hyperintense, and T1 hypointense lesions and for percentage of brain volume change. Findings were compared across subgroups by treatment and baseline characteristics.

Setting: Worldwide, multicenter clinical trial.

Patients: Patients were part of the fingolimod FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) clinical trial for relapsing-remitting multiple sclerosis (N=1272).

Main Outcome Measures: We measured the effect of therapy on acute inflammatory activity, burden of disease, and irreversible loss of brain volume.

Results: Fingolimod therapy resulted in rapid and sustained reductions in inflammatory lesion activity as assessed by gadolinium-enhancing and new/newly enlarged T2 lesions after 6, 12, and 24 months of therapy (P < .001, all comparisons vs placebo). Changes in T2 hyperintense and T1 hypointense lesion volume also significantly favored fingolimod (P < .05, all comparisons). Fingolimod, 0.5 mg (licensed dose), significantly reduced brain volume loss during months 0 to 6, 0 to 12, 12 to 24, and 0 to 24 (P < .05, all comparisons) vs placebo, and subgroup analyses confirmed these effects over 2 years irrespective of the presence/absence of gadolinium-enhancing lesions, T2 lesion load, previous treatment status, or level of disability.

Conclusion: These results, coupled with the significant reductions in relapse rates and disability progression reported previously, support the positive impact on long-term disease evolution.

Trial Registration: clinicaltrials.gov Identifier: NCT00289978


Modulation of S1PRs on lymphocytes by fingolimod retains circulating lymphocytes in the lymph nodes, thereby reducing the recirculation of autoreactive lymphocytes and preventing their infiltration into the central nervous system.1-4 In addition, preclinical studies suggest that fingolimod limits demyelination and restores the function of neural cells.1-3 In an in vivo model,6 experimental autoimmune encephalomyelitis progression in mice required the presence of S1PR subtype 1 (S1P1) on astrocytes. Experimental autoimmune encephalomyelitis scores and spinal cord demyelination/
neurodegeneration were strikingly reduced in mice lacking astrocytic S1P1, suggesting a beneficial effect of functional S1P1 antagonism in astrocytes, in addition to the known peripheral anti-inflammatory effects of fingolimod.1

Inflammatory pathology in MS can be visualized by counting gadolinium (Gd)-enhancing lesions on T1-weighted images7 or new and enlarging T2 lesions on serial magnetic resonance imaging (MRI) scans. These lesions represent areas of recent inflammation and correlate with relapse rates in the short term.8 The extent of hypointense areas on T2-weighted images provides an indication of overall burden of disease (often referred to as T2 burden of disease),9 although it lacks pathological specificity because areas of hyperintensity can represent acute inflammation and edema or demyelination, gliosis, and permanent axonal loss.10

Neurodegenerative pathology in MS can be assessed using other conventional MRI techniques: evaluation of T1 hypointense lesions in T1-weighted images and measures of brain volume, including change in volume over time. Chronic T1 hypointense lesions, also called “black holes,” represent areas of severe demyelination, axonal injury, and matrix destruction.10-13 Brain atrophy is the consequence of permanent neuroaxonal loss (a key pathological feature in MS progression) and can be observed during the earliest stages of MS.14-16 It occurs at an accelerated rate compared with healthy individuals and is widely considered to be the main pathological substrate of irreversible disability.7,15,17,18 Overall change in brain volume is considered to be among the best studied and most reliable in vivo measures of neurodegeneration, has a significant correlation with physical disability, and seems to be a stronger predictor of future disability than lesion-based MRI measures.7,15,19 However, several factors must be considered when interpreting changes in brain volume. Brain volume loss per se is not specific for neuroaxonal loss (ie, neurodegeneration). The early, acute reductions in brain volume reported during the first few months with established anti-inflammatory MS therapies20-22 may represent a reduction in inflammation-associated edema, a phenomenon described as pseudatrophy.17,23 Reduction in the rate of brain volume loss may therefore represent either an anti-inflammatory effect in the setting of inflammation and edema or another mechanism independent of inflammation as yet unidentified; such effects are not easily differentiated in human studies.

Herein, we report the MRI results of a randomized, placebo-controlled, phase 3 study of fingolimod in patients with relapsing-remitting MS, in which patients treated with fingolimod had significant reductions in annualized relapse rate and confirmed disability progression over 2 years, compared with placebo. The present analysis evaluated the effect of therapy on acute inflammatory activity, burden of disease, and irreversible loss of brain volume.

### METHODS

FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) was a randomized, double-blind, placebo-controlled, phase 3 trial involving 138 centers in 22 countries from January 2006 to July 2009.24 It was conducted in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice25 and the Declaration of Helsinki.26 An independent steering committee
The study design and inclusion/exclusion criteria have been published previously, in accordance with the CONSORT guidelines. Briefly, patients were randomly assigned (1:1:1 ratio) to once-daily fingolimod capsules, 0.5 mg or 1.25 mg, or matching placebo for 24 months. Patients had to be aged 18 to 55 years, had to have been discontinued for 6 months or more before randomization, and a score of 0 to 5.5 on the Expanded Disability Status Scale (EDSS). Key exclusion criteria were relapse or clinical activity within 30 days before randomization, active infection, drug- or disease-induced immune suppression, or clinically significant systemic disease. Interferon beta or glatiramer acetate therapy had to have been stopped 3 months or more before randomization. Other previous therapies had to have been discontinued for 6 months or more before randomization. Patients were also excluded if they were unable to undergo MRI scans, including those with claustrophobia or a history of severe hypersensitivity to Gd–diethylene triamine pentaacetic acid.

MRI PROCEDURES

Standardized MRI scans were obtained at screening and at 6, 12, and 24 months and were analyzed centrally at the Medical Image Analysis Center at the University Hospital in Basel, Switzerland. The central reader checked scans for completeness and quality, after which all scans were analyzed by trained technicians and reviewed by radiologists, all of whom were unaware of study-group assignments. Details of MRI assessments are provided in the eAppendix (http://www.archneurol.com).

At each study visit, T1-weighted images, before and after administration of contrast medium (single dose of 0.1 mmol/kg intravenously), and T2-weighted images (T2 and proton density) were obtained according to a standardized imaging protocol (eTable) at certified sites. Investigators were requested to avoid carrying out MRI scans within 30 days of initiation of steroid treatment.

Lesions were identified and marked by radiologists or specially trained personnel on the digital images following a standardized operating procedure. In case of doubt, lesions were discussed in consensus reading sessions. Once lesions were identified, volume calculations were performed by other specially trained technicians (mean intratechnician variability of 3.02% within the MS MRI team at the Medical Image Analysis Center) using an interactive segmentation program developed on the Amira platform (Mercury Computer Systems GmbH). After lesions were marked and segmented, these processes were reviewed and approved by a radiologist.

Percentage of brain volume change (PBVC) between baseline and each postbaseline scan was calculated using the SIENA software included in the Functional Magnetic Resonance Imaging of the Brain software library (FMRIB Analysis Group, Oxford University). At baseline, the single-point SIENA cross-sectional counterpart, SIENAX, was used to estimate the normalized brain volume.
assessed in a pairwise manner and missing data were not imputed. Between-group differences in the numbers of new/newly enlarged T2 lesions were assessed using a negative binomial model adjusted for treatment and country. Rank analysis of covariance adjusted for treatment, country, and baseline number or volume of Gd-enhancing lesions was used to assess between-group differences in the number or volume of Gd-enhancing lesions, respectively. The proportions of patients who were free from Gd-enhancing T1 lesions or new inflammatory activity (Gd-enhancing lesions and new/newly enlarged T2 lesions) were analyzed using a logistic regression model adjusted for treatment, country, and baseline number of Gd-enhancing T1 lesions. The proportions of patients who were free from new/newly enlarged T2 lesions were analyzed using a logistic regression model adjusted for treatment and country (no baseline T2 counts were performed). Absolute and percentage of changes from baseline in the total volume of T2 lesions or T1 hypointense lesions were assessed by rank analysis of covariance adjusted for treatment, country, and corresponding baseline lesion volume (T2 or T1 hypointense volume, respectively). Between-group differences in PBVC were assessed using rank analysis of covariance adjusted for treatment, baseline normalized brain volume, and region. Post hoc subgroup analyses were performed to assess PBVC according to baseline treatment status (treatment-naive or previously treated), EDSS score (0-3.5 points or >3.5 points), Gd-enhancing lesion status (present or absent), or T2 lesion vol-

<table>
<thead>
<tr>
<th>Table 3. Magnetic Resonance Imaging Outcomes for Volume of T2 Lesions and T1 Hypointense Lesions (Intent-to-Treat Population)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fingolimod, 1.25 mg</strong> (n = 429)</td>
</tr>
<tr>
<td><strong>T2 Lesion Load</strong></td>
</tr>
<tr>
<td>Absolute change in T2 lesion volume from baseline to month 12, mm³</td>
</tr>
<tr>
<td>Patients with data, No.</td>
</tr>
<tr>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Median (range)</td>
</tr>
<tr>
<td>P value vs placebo</td>
</tr>
<tr>
<td>Absolute change in T2 lesion volume from baseline to month 24, mm³</td>
</tr>
<tr>
<td>Patients with data, No.</td>
</tr>
<tr>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Median (range)</td>
</tr>
<tr>
<td>P value vs placebo</td>
</tr>
<tr>
<td>Percentage of change in T2 lesion volume from baseline to month 12, mm³</td>
</tr>
<tr>
<td>Patients with data, No.</td>
</tr>
<tr>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Median (range)</td>
</tr>
<tr>
<td>P value vs placebo</td>
</tr>
<tr>
<td>Percentage of change in T2 lesion volume from baseline to month 24, mm³</td>
</tr>
<tr>
<td>Patients with data, No.</td>
</tr>
<tr>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Median (range)</td>
</tr>
<tr>
<td>P value vs placebo</td>
</tr>
<tr>
<td><strong>T1 Hypointense Lesion Load</strong></td>
</tr>
<tr>
<td>Absolute change in T1 hypointense lesion volume from baseline to month 24, mm³</td>
</tr>
<tr>
<td>Patients with data, No.</td>
</tr>
<tr>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Median (range)</td>
</tr>
<tr>
<td>P value vs placebo</td>
</tr>
<tr>
<td>Percentage of change in T1 hypointense lesion volume from baseline to month 24, mm³</td>
</tr>
<tr>
<td>Patients with data, No.</td>
</tr>
<tr>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Median (range)</td>
</tr>
<tr>
<td>P value vs placebo</td>
</tr>
</tbody>
</table>

Abbreviation: ellipses, not applicable.

a P values calculated using rank analysis of covariance adjusted for treatment, country, and volume of corresponding lesions at baseline.
b P values based on descriptive statistics.
volume (≤3300 mm³ or >3300 mm³); details of these analyses are provided in the eAppendix. No adjustment for multiple analyses was performed for the secondary or post hoc analyses.

RESULTS

STUDY POPULATION

Baseline patient demographics and MRI characteristics were broadly similar across treatment groups (Table 1); although baseline MRI parameters for the fingolimod, 1.25 mg, group were slightly worse than fingolimod, 0.5 mg, and placebo, these differences were not clinically meaningful. In total, 1033 of 1272 patients (81.2%) completed the 24-month study, with 945 individuals (74.3%) still receiving the assigned study drug.24 The number of evaluable MRI scans at baseline and months 6, 12, and 24 are reported in Tables 1, 2, and 3 for each of the assessed MRI outcomes. Across treatment groups, evaluable MRI scans and brain volume data were available in 98.6% to 99.8% of patients at baseline, 89.2% to 96.0% at month 6, 85.2% to 94.4% at month 12, and 77.9% to 87.5% of individuals at month 24. Reasons for missing scans were not collected. As stated in the “Methods” section, no adjustment was made for multiple analyses.

INFLAMMATORY LesION ACTIVITY

Both fingolimod doses reduced the number of new/newly enlarged T2 lesions over 24 months compared with placebo (P < .001); the reductions were significant by month 6 and remained so during the 24-month study (P < .001 for all comparisons of fingolimod vs placebo) (Table 2). Patients treated with either dose of fingolimod also had fewer Gd-enhancing lesions and lower Gd-enhancing lesion volumes at each postbaseline MRI assessment than patients treated with placebo (P < .001 for all comparisons).

More patients receiving fingolimod than those receiving placebo were free from new/newly enlarged T2 lesions, Gd-enhancing lesions, or both (ie, free of new inflammatory activity) at all assessments throughout the study (P < .001) (Figure 1).

T2 BURDEN OF DISEASE

Burden of disease evolution, as assessed by change in T2 lesion volume, was lower in patients treated with either dose of fingolimod over 24 months than with placebo (P < .001 for all comparisons) (Table 3). Absolute T2 lesion volume decreased slightly from baseline to months 12 or 24 in both fingolimod groups and increased in the placebo group.

T1 HYPOINTENSE LesION VOLUME

Total T1 hypointense lesion volume remained stable during months 0 to 24 in patients receiving fingolimod, while a slight increase was observed in the placebo group. The difference in change from baseline to month 24 favored both doses of fingolimod over placebo (P < .05 for all comparisons) (Table 3).

BRAIN VOLUME CHANGE

As reported previously,24 both fingolimod doses reduced mean PBVC during months 0 to 24 compared with placebo in the overall study population (P < .001). This reduction in PBVC was significant by month 6 and was
sustained during months 0 to 12 and 12 to 24 (P < .05 for both doses at all 3 intervals) (Figure 2A). The relative reduction in brain volume loss for fingolimod, relative to placebo, ranged from 23% to 45% at the various intervals.

To evaluate the influence of the anti-inflammatory effect of fingolimod on brain volume change, the results were stratified according to whether patients had Gd-enhancing lesions at baseline. The first finding of note is that brain volume declined approximately twice as quickly in patients with Gd-enhancing lesions at baseline as in those without Gd-enhancing lesions in both the placebo and fingolimod groups. Second, irrespective of baseline Gd-enhancing lesion activity, both fingolimod doses significantly reduced brain volume loss over 2 years compared with placebo (Figure 2B and C). Finally, the temporal evolution of brain volume loss differed between patients with Gd-enhancing lesions at baseline and those without (Figure 2B and C). For individuals with active inflammation at baseline (Gd-enhancing lesions present), brain volume in the placebo group decreased steadily throughout the study and at a faster rate than in those without Gd-enhancing lesion activity. In patients receiving fingolimod, brain volume loss occurred at a similar rate to placebo during the first 6 months, slowed slightly during the second 6 months, and then was considerably slower than placebo during the second year. For patients without Gd-enhancing lesions at baseline, brain volume again decreased steadily in those receiving placebo. In contrast, with fingolimod therapy, there was an immediate reduction in the rate of brain volume loss compared with placebo, which was greatest during the first 6 months and relatively steady thereafter but progressed more slowly than placebo. No significant differences in the magnitude of the effect between the 2 fingolimod doses were noted (P > .10 for subgroup interactions). At no point did the rate of brain volume loss in fingolimod-treated patients exceed that in the placebo group, irrespective of baseline MRI activity.

Other subgroup analyses (Table 4) assessing PBVC during months 0 to 24 indicated that both fingolimod doses were superior to placebo irrespective of T2 lesion volume at baseline (≤3300 mm³ or >3300 mm³) and that fingolimod, 0.5 mg, was superior to placebo regardless of whether patients had received disease-modifying therapy for MS; the difference approached significance.

Figure 2. Mean percentage of brain volume change (PBVC) from baseline in the overall study population (A) and in patients with (B) or without (C) gadolinium (Gd)-enhancing lesions at baseline.
for fingolimod, 1.25 mg, in previously treated patients. Brain volume loss was also significantly reduced by both fingolimod doses in individuals with EDSS scores of 0 to 3.5; although a similar numerical difference was observed in those with scores more than 3.5 ($P = .50$ for subgroup interaction between patients with lower and higher EDSS scores), the difference did not reach significance compared with placebo in this smaller subgroup. Patients with higher EDSS scores and larger T2 volumes at baseline had greater degrees of brain volume loss than their complementary group (both placebo and fingolimod groups). There was relatively little difference in the extent of brain volume loss between groups segregated by previous therapy status.

Overall, the magnitude of PBVC, relative to placebo, ranged from 24% to 49% for the various subgroups, with the greatest relative changes seen in the previously treated fingolimod, 0.5 mg, group and the smallest relative effect in the treatment-naive fingolimod, 0.5 mg, group. However, effect size was reversed in these same subgroups for the fingolimod, 1.25 mg, group.

**COMMENT**

These analyses from the 2-year FREEDOMS study confirm that the efficacy of fingolimod therapy is robust across all MRI end points. The anti-inflammatory effects of fingolimod therapy, as depicted by Gd-enhancing lesions and new/newly enlarged T2 lesions, were evident as early as 6 months after treatment initiation and were sustained over 2 years. Approximately half the patients receiving fingolimod therapy were free from any new inflammatory lesions throughout this 2-year study.
**FREEDOMS Study Group Investigators**

**Data and Safety Monitoring Board**

T. Calandra, Centrum Hospitalier Universitaire Vaudois, Lausanne, Switzerland; J. DiMarco, University VA Health System–Cardiology, Charlottesville, Virginia; J. D. Easton (chair), Rhode Island Hospital–Brown Medical School, Providence, Rhode Island; L. D. Hudson, University of Washington, Seattle; J. Kesselring, Neurology, Rehabilitation Center, Valens, Switzerland; A. Laupacis, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada; N. Temkin, University of Washington, Redmond; B. G. Weinschenker, Mayo Clinic College of Medicine, Rochester, Minnesota; M. Zarin, Institute of Ophthalmology and Visual Sciences, University of Medicine and Dentistry of New Jersey Medical School/Ophthalmology, Newark.

**Steering Committee**

P. Calabresi, Johns Hopkins Hospital, Baltimore, Maryland; R. Hohlfeld, Institut für Klinische Neuroimmunologie, München, Germany; L. Kapus (chair), University Hospital, Basel, Switzerland; P. O’Connor, St Michael’s Hospital, Toronto, C. Polman, VU University Medical Center, Amsterdam, the Netherlands.

**Principal Investigators (Responsible for Data Collection)**

Australia: R. Beran, Strategic Health Evaluators, Chatswood; M. Paine, St Vincent’s Hospital, Fitzroy; R. MacDonell, (N-CRESS) Neuroimmunology Clinical Research Institute, Heidelberg; G. Riordan, North Melbourne Hospital, Melbourne; A. Summerfield, Queen Elizabeth Hospital, Woodville; Belgium: L. Van Opdenbosch, Algemeen Ziekenhuis St Jan, Brugge; E. Bartholome and M. Pandolfini, CHU Erasme, Brussels; P. Seelnders, CHU Charleroi Hôpital Civil, Charleroi; B. Dubet, UZ Gasthuisberg, Leuven; J. De Vleeschauwer, CHU Saint-Pierre, Brussels; France: P. Clavelou, Hôpital Gabriel Montpied Neurologie, Clermont-Ferrand; T. Moreau, Hôpital Général–CHU Dijon, Dijon; P. Verderio, Terveystalo, Tampere; J.-P. Eralinna, Suomen Terveystalo Clinical Research Oy, Turku; L. Airas, Turun Yliopistollinen Keskussairaala, Turku; K. Bendfeldt and E. W. Radue, University Hospital, Basel, Switzerland.

Czech Republic: M. Černý, Milosrdná Nemocnice, Prague; M. Štastný, MS Centrum, Prague; J. Vacek, MS Kroměříž; J. Vacek, MS U Přerova; E. Havrdová, MS Zlín; L. Pazdera, O Vysata, Centrum Neurologicke Pece v Rychnova nad Kněžnou; M. Vachova, Krajské Zdravotnictví, AS–Nemocnice Teplice, OP, Teplice; Estonia: K. Gross-Paju, Laane-Tallinna Keskkogla, Tallinn; Finland: M. Kallela, Postitalon Laakarilaitos, Helsinki; E. Kinnunen, Hyvinkää Sairaala, Hyvinkää; M.-L. Sumelahti, Suomen Yliopisto, Turku; Greece: J. D. Easton (chair), Rhode Island Hospital–Brown Medical School, Providence, Rhode Island; M. Beraldino, Universita Telescopio de C widesky, Bialystok; W. Drozdowski, Samodzielny Publiczny Szpital Kliniczny, Bialystok; W. Fryze, Wojewódzki Szpital Specjalizacyjny im. M. Ryczynd nad Kneznou; M. Vachova, Krajské Zdravotnictví, AS–Nemocnice Teplice, ZP, Teplice; Hungary: K. Bendfeldt and E. W. Radue, University Hospital, Basel, Switzerland.

Ireland: M. Hickey, Beaumont Hospital, Dublin; I. Rektor, Faculty Hospital St Anne, Brno; V. Ondrich, Military Hospital, Brno; P. Kanovsky, Faculty Hospital, Olomouc; O. Zapletalova, St Michael’s Hospital, Toronto; V. Devonshire, MS Clinical Research Group, UBC Hospital, Vancouver, British Columbia; Czech Republic: I. Kumlukova, MS Centrum, Prague; E. Havrdová; MS Zlín; J. Vacek, MS U Přerova; E. Havrdová, MS Zlín; L. Pazdera, O Vysata, Centrum Neurologicke Pece v Rychnova nad Kněžnou; M. Vachova, Krajské Zdravotnictví, AS–Nemocnice Teplice, OP, Teplice; Estonia: K. Gross-Paju, Laane-Tallinna Keskkogla, Tallinn; Finland: M. Kallela, Postitalon Laakarilaitos, Helsinki; E. Kinnunen, Hyvinkää Sairaala, Hyvinkää; M.-L. Sumelahti, Suomen Yliopisto, Turku; Greece: J. D. Easton (chair), Rhode Island Hospital–Brown Medical School, Providence, Rhode Island; M. Beraldino, Universita Telescopio de C widesky, Bialystok; W. Drozdowski, Samodzielny Publiczny Szpital Kliniczny, Bialystok; W. Fryze, Wojewódzki Szpital Specjalizacyjny im. M. Ryczynd nad Kneznou; M. Vachova, Krajské Zdravotnictví, AS–Nemocnice Teplice, ZP, Teplice; Hungary: K. Bendfeldt and E. W. Radue, University Hospital, Basel, Switzerland.

 Austria: I. Rektor, Faculty Hospital St Anne, Brno; V. Ondrich, Military Hospital, Brno; P. Kanovsky, Faculty Hospital, Olomouc; O. Zapletalova, Faculty Hospital of Ostrava, Ostrava; Z. Amliber, Faculty Hospital of Pilsen, Pilsen; E. Ehler, Neurologische Klinik, Prag; E. Meluzhova, Hospital Motol, Prague; P. Kremenchutzky, University Hospital, Basel, Switzerland.

Ireland: M. Hickey, Beaumont Hospital, Dublin; I. Rektor, Faculty Hospital St Anne, Brno; V. Ondrich, Military Hospital, Brno; P. Kanovsky, Faculty Hospital, Olomouc; O. Zapletalova, Faculty Hospital of Ostrava, Ostrava; Z. Amliber, Faculty Hospital of Pilsen, Pilsen; E. Ehler, Neurologische Klinik, Prag; E. Meluzhova, Hospital Motol, Prague; P. Kremenchutzky, University Hospital, Basel, Switzerland.

Ireland: M. Hickey, Beaumont Hospital, Dublin; I. Rektor, Faculty Hospital St Anne, Brno; V. Ondrich, Military Hospital, Brno; P. Kanovsky, Faculty Hospital, Olomouc; O. Zapletalova, Faculty Hospital of Ostrava, Ostrava; Z. Amliber, Faculty Hospital of Pilsen, Pilsen; E. Ehler, Neurologische Klinik, Prag; E. Meluzhova, Hospital Motol, Prague; P. Kremenchutzky, University Hospital, Basel, Switzerland.

Ireland: M. Hickey, Beaumont Hospital, Dublin; I. Rektor, Faculty Hospital St Anne, Brno; V. Ondrich, Military Hospital, Brno; P. Kanovsky, Faculty Hospital, Olomouc; O. Zapletalova, Faculty Hospital of Ostrava, Ostrava; Z. Amliber, Faculty Hospital of Pilsen, Pilsen; E. Ehler, Neurologische Klinik, Prag; E. Meluzhova, Hospital Motol, Prague; P. Kremenchutzky, University Hospital, Basel, Switzerland.

Ireland: M. Hickey, Beaumont Hospital, Dublin; I. Rektor, Faculty Hospital St Anne, Brno; V. Ondrich, Military Hospital, Brno; P. Kanovsky, Faculty Hospital, Olomouc; O. Zapletalova, Faculty Hospital of Ostrava, Ostrava; Z. Amliber, Faculty Hospital of Pilsen, Pilsen; E. Ehler, Neurologische Klinik, Prag; E. Meluzhova, Hospital Motol, Prague; P. Kremenchutzky, University Hospital, Basel, Switzerland.
compared with only 21% of patients receiving placebo. The rapid anti-inflammatory effect of fingolimod is corroborated by a 6-month, placebo-controlled, phase 2 study of fingolimod.29 In this phase 2 study, significant reductions in the number of Gd-enhancing lesions were detected after only 2 months and at each monthly MRI up to month 6 compared with placebo.

Importantly, the rate of brain volume loss over 2 years was significantly reduced by fingolimod therapy vs placebo in the overall study population. This effect was evident by month 6 and was sustained during the remainder of the 2-year study. These data are consistent with results of the companion 1-year Trial Assessing Injectable Interferon Versus FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS) study comparing fingolimod with intramuscular interferon beta-1a.30 In TRANSFORMS, fingolimod reduced brain volume loss relative to intramuscular interferon beta-1a during the controlled phase of the study, while patients switching from intramuscular interferon beta-1a to fingolimod in the 1-year extension experienced marked slowing of brain atrophy.31

In contrast to consistent benefits of fingolimod therapy on brain atrophy observed in FREEDOMS and TRANSFORMS, similar phase 3 studies of interferon beta or natalizumab have shown an early acceleration of brain volume loss (equal to or exceeding that of controls) during the first year of treatment and a slowing during the second year, but no significant difference over 2 years.32,33,34 For instance, in the AFFIRM study of natalizumab,35,36 brain volume loss over 2 years was similar in the natalizumab (−0.80%) and placebo (−0.82%) groups but during the first year was greater with natalizumab (−0.56%) than with placebo (−0.40%). The observed average rate of brain volume loss in patients in the placebo and intramuscular interferon beta-1a groups in FREEDOMS and TRANSFORMS ranged from 0.40% to 0.56% during the first year,32,34,35,36 values that are consistent with the natalizumab studies but at the lower end of those reported previously for patients with relapsing-remitting MS (0.5%–1.35% per year).32,33,34 This is consistent with a population of patients that has shorter disease duration (<10 years) and low disability (median EDSS score of 2.0) compared with earlier studies or natural history cohorts.37

In the present study, the subgroup analyses revealed more about the nature of the reductions in brain volume loss during fingolimod therapy. In patients with Gd-enhancing lesions at baseline, the greater rate of brain volume loss in year 1 than in year 2 in patients treated with fingolimod may be consistent with the presence of some degree of pseudoatrophy. In these individuals, the anti-inflammatory effect of fingolimod results in fewer lesions32,37 and reduced edema and may lead to initial loss of brain volume compared with those without Gd-enhancing lesions at baseline. The fact that this does not lead to a greater rate of brain volume loss than in the placebo group, as seen with other MS therapies,17 may either reflect a weaker anti-inflammatory effect of fingolimod or other as-yet unidentified mechanism independent of inflammation. However, the rapid and significant reductions in Gd-enhancing lesions indicate that fingolimod has potent anti-inflammatory effects similar to other therapies.32

Brain atrophy is widely recognized as a useful marker for monitoring disease progression in MS.13,18 The clinical relevance of therapeutically reduced brain volume loss is underscored by the observations that atrophy is evident during the earliest stages of MS,7,19 proceeds relentlessly throughout the course of MS at higher rates than in healthy individuals,10,19 and has a significant correlation with physical disability.10,19 Furthermore, brain atrophy is considered to be a better MRI predictor of future disability than T2 lesion load or T1 hypointense lesion load.7,13,19 Therefore, the significant reduction in brain atrophy over 2 years with fingolimod therapy complements the reported reductions in relapse rate and disability progression vs placebo.

Accepted for Publication: March 28, 2012. 
Published Online: July 2, 2012. doi:10.1001/archneurol.2012.1051

Author Affiliations: Medical Image Analysis Center (Drs Radue and Mueller-Lenke) and Departments of Neurology and Biomedicine (Dr Kappos), University Hospital, and Novartis Pharma AG (Drs Agoropoulou, de Vera, Zhang-Auberson, and Burtin), Basel, Switzerland; St Michael’s Hospital, Toronto, Ontario, Canada (Dr O’Connor); VU Medical Center, Amsterdam, the Netherlands (Dr Polman); Institute for Clinical Neuroimmunology, Klinikum der LMU München, Munich, Germany (Dr Hohlfeld); Johns Hopkins Hospital, Baltimore, Maryland (Dr Calabresi); Department of Neurology, Medical Academy of Lodz, Lodz, Poland (Dr Selmaj); and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (Drs Holdbrook and Francis).

Correspondence: Ernest-Wilhelm Radue, MD, Medical Image Analysis Center, University Hospital, Basel, Schanzenstrasse 55, CH-4031 Basel, Switzerland (eradue@uhbs.ch).

Author Contributions: All authors take full responsibility for the content of the article. Dr Radue had full access to all of the study data and takes full responsibility for the integrity of the data and the accuracy of the data.
analyses. All authors were involved in the decision to submit the manuscript for publication. Study concept and design: Radue, Polman, Calabresi, Agoropoulou, de Vera, Zhang-Auberson, Burtin, and Kappos. Acquisition of data: Radue, Polman, Hohlfeld, Calabresi, Mueller-Lenke, Agoropoulou, de Vera, and Kappos. Analysis and interpretation of data: Radue, O’Connor, Polman, Hohlfeld, Calabresi, Selmaj, Agoropoulou, Holdbrook, de Vera, Zhang-Auberson, Francis, Burtin, and Kappos. Drafting of the manuscript: de Vera, Zhang-Auberson, and Francis. Critical revision of the manuscript for important intellectual content: Radue, O’Connor, Polman, Hohlfeld, Calabresi, Selmaj, Mueller-Lenke, Agoropoulou, Holdbrook, de Vera, Zhang-Auberson, Francis, Burtin, and Kappos. Statistical analysis: Holdbrook, de Vera, and Francis. Administrative, technical, and material support: Radue, Hohlfeld, and Zhang-Auberson. Study supervision: Radue, Polman, Hohlfeld, Calabresi, Mueller-Lenke, de Vera, Zhang-Auberson, Francis, and Burtin.

Financial Disclosure: Dr Radue has received personal compensation from Bayer Schering, Biogen Idec, Novartis, and Merck Serono for consulting and speaking services and financial support for research activities from Actelion, Basilea Pharmaceutica Ltd, Biogen Idec, Merck Serono, and Novartis. Dr O’Connor has received personal compensation for consulting and serving on scientific advisory boards and research funding from Novartis Pharma AG. Dr Polman has received honoraria and/or consultation fees and/or research support from Actelion, Biogen Idec, Bayer Schering, GlaxoSmithKline, Merck Serono, Novartis, Roche, Teva, and UCB. Dr Hohlfeld has received personal compensation for serving on scientific advisory boards and/or speaking activities as principal or on advisory boards from Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, sanofi-aventis, and Teva and research grant support from Bayer Schering Pharma, Biogen Idec, Novartis, sanofi-aventis, and Teva. Dr Calabresi has received personal compensation for consulting and serving on scientific advisory boards and/or speaking activities from Abbott, Biogen Idec, EMD-Serono, Genentech, Teva, and Vertex. Dr Selmaj has received honoraria and/or consultation fees and/or research support from Biogen Idec, Genzyme, Merck Serono, Novartis, ONO Pharmaceuticals, and Roche. Drs Agoropoulou, Burtin, de Vera, and Zhang-Auberson are employees of Novartis Pharma AG. Drs Holdbrook and Francis are employees of Novartis Pharmaceuticals Corporation. Dr Kappos has received compensation, used as research funding, for consulting, serving on scientific advisory boards, acting as a clinical trial principal investigator and member or chair of planning and steering committees, and/or speaking activities as principal or on advisory boards from Actelion, Advancell, Allozyne, BaroFold, Bayer HealthCare, Bayer Schering Pharma, Bayhill, Biogen Idec, BioMarin, CSL Behring, Elan, GENmab, GeNeuro SA, GenMark, GlaxoSmithKline, Lilly, Merck Serono, MediciNova, Novartis, Novo Nordisk, Pептидные, sanofi-aventis, Santhera, Roche, Teva, UCB, and Wyeth. Research and clinical operations (nursing and patient care services) at the MS Center in Basel have been supported by unrestricted grants from 1 or more of these companies and by grants from the Swiss MS Society, the Swiss National Research Foundation, the European Union, the Gianni Rubatto Foundation, Novartis, and the Roche Research Foundation.

Funding/Support: The study was funded by Novartis Pharma AG, Basel, Switzerland.

Online-Only Material: The eAppendix and eTable are available at http://www.archneurol.com.

Additional Contributions: We thank the patients and investigators who took part in this study. They thank Hashem Salloukh of Novartis Pharma AG and Tom Potter and Sarah Griffiths of Oxford PharmaGenesis Ltd for editorial assistance, collating comments from authors and other named contributors, and editing the manuscript for submission. Such editorial help was funded by Novartis Pharma AG.

REFERENCES


